Pharmacoeconomic Evaluation of Antimuscarinic Agents for the Treatment of Overactive Bladder
- 1 December 2006
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (12), 1694-1702
- https://doi.org/10.1592/phco.26.12.1694
Abstract
Study Objective. To compare the cost‐effectiveness of various antimuscarinic agents for the treatment of overactive bladder (OAB).This publication has 43 references indexed in Scilit:
- Costs Associated with the Management of Overactive Bladder and Related ComorbiditiesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- Oxybutynin Extended-ReleaseDrugs, 2004
- Estimated economic costs of overactive bladder in the United StatesUrology, 2003
- Prospective, Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA TrialMayo Clinic Proceedings, 2003
- Prevalence and burden of overactive bladder in the United StatesWorld Journal of Urology, 2003
- The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence SocietyUrology, 2003
- Definition and epidemiology of overactive bladderUrology, 2002
- The Overactive Bladder: A Nursing PerspectiveThe American Journal of Nursing, 2002
- Dry mouth with conventional and controlled-release oxybutynin in urinary incontinencePublished by Ovid Technologies (Wolters Kluwer Health) ,2000
- ONCE DAILY CONTROLLED VERSUS IMMEDIATE RELEASE OXYBUTYNIN CHLORIDE FOR URGE URINARY INCONTINENCEJournal of Urology, 1999